Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in the following upcoming investor conferences:

The FDA issues a CRL to Blueprint Medicines' (BPMC) NDA for Ayvakit to treat adults with unresectable/metastatic fourth-line GST.

Blueprint Medicines (BPMC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the first quarter ended March 31, 2020.

Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines conference call. This is Kristin Hodous of Blueprint Medicines, and welcome to Blueprint Medicines' first-quarter 2020 financial and operating results conference call.

A closely watched drug candidate didn't meet the primary endpoint of a late-stage trial, which creates a wide-open opportunity for a competitor.

Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Friday, May 29, 2020 to review updated clinical data for pralsetinib in RET-altered cancers. The data will also be presented in the American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program, May 29-31, 2020.

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 1.86% and 27.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the achievement of key milestones reflecting portfolio-wide progress against the company's 2020 goals. These milestones include the compilation of top-line data for pralsetinib in patients with RET-mutant medullary thyroid cancer (MTC), supporting plans to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in the second quarter of 2020.

Right now, Blueprint Medicines Inc. (NASDAQ: BPMC) share price is at $59.15, after a 16.6% decrease. Over the past month, the stock spiked by 1.15%, but over the past year, it actually decreased by 20.37%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.The stock is currently trading above from its 52 week low by 36.64%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with Biotechnology stocks, and capitalize on the lower share price observed over the year.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Blueprint Medicines has a lower P/E than the aggregate P/E of 6.08 of the biotechnology industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.There are many limitations to P/E ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * Stocks That Hit 52-Week Lows On Tuesday * Stocks That Hit 52-Week Highs On Tuesday * Sharps Compliance: Q3 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

If you own shares in Blueprint Medicines Corporation (NASDAQ:BPMC) then it's worth thinking about how it contributes...

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of avapritinib for the treatment of adults with unresectable or metastatic fourth-line gastrointestinal stromal tumor (GIST). The CRL states that the FDA cannot approve the application.

Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced top-line results from the Phase 3 VOYAGER clinical trial of avapritinib versus regorafenib in patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST). The VOYAGER trial did not meet the primary endpoint of an improvement in progression-free survival (PFS) for avapritinib versus regorafenib. Top-line safety data for avapritinib were consistent with those previously reported.

Shares of the company fell 3.5% to $62.02 in premarket trading. The regulator in its so-called complete response letter said that Blueprint's application could not be approved in the current form. The company was looking to win approval for the therapy, Ayvakit, in patients with gastrointestinal stromal tumor (GIST), who have exhausted all other treatment options.

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

Q1 2020 Blueprint Medicines Corp Earnings Call

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to present updated clinical data for pralsetinib in RET-altered cancers and avapritinib in systemic mastocytosis.

Blueprint Medicines (BPMC) betters loss estimates while revenues beat the mark in the first quarter. Higher collaboration revenues and a surge in product sales aid results.

Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).